Royal Bank of Canada’s GlucoTrack GCTK Stock Holding History

Royal Bank of Canada’s Portfolio GCTK Stock Details GCTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	–	–	7525
2026 Q1	$0	Buy	+1	New	+$2	﹤0.01%	7325

Other funds holding GCTK

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

GIPW

Granite Islands Private Wealth Guilford, Connecticut $135M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Royal Bank of Canada's GCTK Position: Q2 2026 in Review

Royal Bank of Canada sold out of GlucoTrack (GCTK) in Q2 2026, closing a stake of 1 share.

Royal Bank of Canada first reported a position in GCTK in Q1 2026 and held it in 1 quarter. The position peaked at $0 in Q1 2026. 18 funds tracked by Wall St. Rank hold GCTK as of Q2 2026.

Royal Bank of Canada reported no remaining GlucoTrack position as of Q2 2026 after selling out during the quarter.
Royal Bank of Canada sold 1 GlucoTrack share in Q2 2026.
Royal Bank of Canada first reported a position in GlucoTrack in Q1 2026 and held it in 1 quarter.
Royal Bank of Canada's GlucoTrack position peaked at $0 in Q1 2026.
18 funds tracked by Wall St. Rank held GlucoTrack as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.